Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
The future price of lecanemab in European countries is unknown.
Why it matters
In a Swedish Markov model, three years of lecanemab for early Alzheimer's disease resulted in 0.13 life-years gained, 0.17 QALYs gained, and a net cost increase of 87,146 SEK before considering the cost of the drug. The cost-effective price at a willingness-to-pay level of 1 million SEK per QALY was 33,886 SEK per year of treatment, and the health gain, net costs, and cost-effective price varied significantly by treatment duration, potential residual effects, and patient characteristics.
-
< 0.001). Receiver operating characteristic (ROC) analysis identified right hippocampal MD and t-tau as optimal classifiers for AD.
Why it matters
This cross-sectional study identified imaging and fluid biomarkers that distinguish different stages of Alzheimer's disease and suggest a staging model of progression. It provides potential markers for monitoring progression but does not test any treatment, cure, or prevention.
-
48/100
This study provided a preliminary examination of indices of obstructive sleep apnea (OSA) and sleep disruptions in adults with Down syndrome (DS), and their associations with Alzheimer's disease (AD) pathology and symptomatology.
Why it matters
In this preliminary study of 93 adults with Down syndrome, most screened positive for obstructive sleep apnea, many were undiagnosed, and greater sleep disruption was associated with more amyloid and tau burden and worse cognition. The authors call this preliminary evidence and no treatment or prevention is tested.
-
Clinical trials of anti-amyloid-β (Aβ) monoclonal antibodies in Alzheimer disease (AD) infer target engagement from Aβ positron emission tomography (PET) and/or fluid biomarkers such as cerebrospinal fluid (CSF) Aβ42/40.
Why it matters
Brain tissue from people who had taken gantenerumab showed lower amyloid plaque levels in most brain regions, in proportion to how much drug they received, while solanezumab showed no such effect. However, tau tangles, microgliosis and astrocytosis did not differ between groups, so this direct tissue evidence shows amyloid removal but no clear effect on other Alzheimer's brain changes.
-
Dementia with Lewy bodies (DLB) frequently coexists with Alzheimer's disease pathology, yet the pattern of cortical microstructural injury and its relationship with amyloid, tau, and cerebrovascular pathologies remains unclear.
Why it matters
In people with dementia with Lewy bodies, brain imaging showed signs of cortical microstructural injury, and modeling suggested APOE genotype influenced amyloid levels, which raised tau, leading to this injury. The authors advocate for multi-target therapeutic approaches addressing both Alzheimer's and Lewy body pathologies, but this study itself did not test a treatment.
-
Alzheimer's disease (AD) diagnosis relies on cerebrospinal fluid (CSF) biomarkers or amyloid PET.
Why it matters
A model using plasma p-Tau217, ApoE and age identified amyloid positivity with good performance, and a two-cut-off strategy classified patients as Alzheimer, non-Alzheimer or uncertain. This is a diagnostic tool and does not show any effect on treating or preventing the disease.
-
Neuropsychological interviews and neuroimaging techniques are traditional diagnostic methods for Alzheimer's disease (AD).
Why it matters
In 51 patients with cognitive impairments, plasma levels of Aβ42, pTau181, and their ratios correlated with CSF levels and showed high accuracy in distinguishing amyloid-positive from amyloid-negative patients. This supports plasma biomarkers as a non-invasive tool for early detection, but it does not treat, cure or prevent Alzheimer's disease.
-
Key markers and mechanisms were identified for each stage: initial neurophysiological deficits in SCD with compensatory metabolomic responses, gut-brain axis dysregulation in MCI, and extensive metabolic disruption and multisystem breakdown in AD.
Why it matters
This study identified stage-specific neural and molecular markers and used machine learning to predict stages of Alzheimer's disease, with electroencephalogram highlighted as a potential early screening tool. It is about detection and staging, not about treating, curing, or preventing the disease.
-
Patients with dementia face increased risks after general anesthesia.
Why it matters
Resting-state EEG showed spectral differences in people with Alzheimer's disease and frontotemporal dementia compared to controls, but processed indices used in anesthesia monitoring did not show a clear trend. This suggests current anesthesia depth monitors may not reflect these dementia-related EEG features, which is relevant to monitoring rather than treatment.
-
Mild cognitive impairment (MCI) is a clinical condition characterized by a decline in cognitive ability and progression of cognitive impairment.
Why it matters
This study compared deep learning and traditional machine learning models for predicting mild cognitive impairment using plasma proteomic biomarkers, with the deep learning model achieving the highest accuracy. This could improve early detection, but no treatment or cure is tested.
-
Alzheimer's Disease (AD) is a progressive condition of a neurological brain disorder recognized by symptoms such as dementia, memory loss, alterations in behaviour, and impaired reasoning abilities.
Why it matters
This study proposes a lightweight neural network for classifying Alzheimer's disease from MRI images and reports that it surpassed other models. It is a technical classification study and does not test any treatment, cure, or prevention.
-
Alzheimer's Disease (AD) is a particular form of dementiacharacterized by a steady decline in brain function and cognitive abilities, leading to memory loss, disorientation, and trouble doing daily tasks.
Why it matters
This study combined several deep learning models to classify stages of Alzheimer's disease from MRI images, achieving 97.31% test accuracy, and developed a web application for doctors. It is a detection method only and does not test any treatment, cure, or prevention.
-
These findings indicate EXT may be more sensitive to Aβ's role in preclinical AD than level and improve targeting of individuals for AD prevention trials.
Why it matters
Measuring how far amyloid has spread across the neocortex detected early amyloid deposits better than measuring amyloid level and improved prediction of cognitive decline and tau spread. This is about improving early detection and trial targeting, not about treating, curing, or preventing Alzheimer's disease.
-
Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease.
Why it matters
This paper describes an expert panel's recommendations to adapt prescribing rules for anti-amyloid antibody treatments so that adults with Down syndrome are not excluded from access. It is about access to potential disease-modifying treatments, not about whether those treatments work.
-
In mild AD patients aged less than 75 years, the mean age-at-diagnosis of AD in APOE4 carriers was reduced by over 6 years in BCHE-K carriers versus noncarriers.
-
To ensure diversity, we developed a comprehensive recruitment strategy using a diverse, culturally‐trained staff that includes : • Identifying Dementia Specialists experienced recruiting minorities • Embedding high‐impact community engagement in select regions • Increasing capacity of specialists and PET facilities to engage minorities • Increasing pipeline of referrals to Dementia Specialists • Creating a culturally‐informed awareness campaign Result New IDEAS has enrolled 4,524 participants including 954 (21.1%) Black/African American, and 842 (18.6%) Hispanic/Latinx.
Why it matters
This study describes a community-engaged recruitment strategy that enrolled 4,524 participants in an amyloid imaging study, including 21.1% Black/African American and 18.6% Hispanic/Latinx participants. It addresses diversity in research participation and does not test a treatment, cure, or prevention for Alzheimer's disease.
-
The devastating effects of Alzheimer's disease (AD) are yet to be ameliorated due to the absence of curative treatment options.
Why it matters
This review pulled together studies that used single-cell or spatial genetic profiling of Alzheimer's brain tissue. It grouped the molecular differences into four areas: sex-specific features, early-onset features, aging and immune pathways, and listed reported drivers such as TREM2, PITRM1, cholesterol breakdown, tau and APOE expression. The authors offer these as leads for future disease-modifying research rather than tested treatments.
-
Our results from 5 patients with eAD treated with LD-WBRT (10 Gy in 5 fractions) demonstrate a positive safety profile and provide preliminary, hypothesis-generating data to suggest that this treatment stabilizes or improves cognition.
Why it matters
In a pilot trial of five patients with early Alzheimer dementia, low-dose whole brain radiation therapy appeared safe and some patients had stable or improved cognition at one year. The authors say these preliminary findings need testing in larger, definitive, randomized trials.
-
Biomarkers of saccade, pupil, and blink were extracted from video-based eye tracking to create a classifier with high sensitivity to the landscape of PD cognitive and motor dysfunction.
Why it matters
A video-based eye tracking classifier distinguished Parkinson's disease and its cognitive stages from healthy controls with an ROC-AUC of 0.88, reaching 0.95 for Parkinson's disease dementia. This concerns Parkinson's disease, not Alzheimer's disease, and does not test any treatment, cure or prevention.
-
Amyloid-related imaging abnormalities (ARIA) is a term introduced in 2010 to encompass a spectrum of MRI findings observed in patients receiving investigational anti-amyloid beta (Aβ) immunotherapies for Alzheimer disease (AD).
Why it matters
This review explains amyloid-related imaging abnormalities (ARIA), a spectrum of MRI findings seen in patients receiving investigational anti-amyloid immunotherapies for Alzheimer's disease. ARIA is often asymptomatic and self-resolving but can lead to pausing or stopping therapy, so it matters for patient selection and monitoring.
-
The microRNAs (miRNAs) are potential biomarkers for complex pathologies due to their involvement in the regulation of several pathways.
Why it matters
This small study of 46 people looked at whether microRNAs in blood could serve as less invasive biomarkers for early Alzheimer disease. It is preliminary and does not test any treatment, so it cannot yet say whether these markers help patients.
-
Genetic pathways implicated in causing AD are related to altered levels of soluble tau through both Aβ-dependent and Aβ-independent mechanisms, which may have relevance for anti-tau drug development.
Why it matters
In the BioFINDER and ADNI cohorts, polygenic risk scores for Alzheimer's disease were associated with CSF tau biomarkers, partly through amyloid pathology and partly independently of it. This is about genetic contributions to tau biomarker levels, not about treating, curing or preventing Alzheimer's disease.
-
Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients to estimate whether aducanumab and donanemab were reasonably priced for the health benefit they provide.
Why it matters
Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients and found that at the prices assumed in the model, both aducanumab and donanemab cost far more per year of good-quality life gained than standard cost-effectiveness benchmarks. Aducanumab performed especially poorly and donanemab needed a much lower price to be considered good value.
-
Our results provide a framework for precision nutrition approaches aiming to modulate the AD gut microbiota.
Why it matters
This study examined gut microbiota composition across the Alzheimer's disease continuum in a Turkish cohort. The authors state their results provide a framework for precision nutrition approaches aiming to modulate the Alzheimer's disease gut microbiota.
-
Alzheimer's disease (AD) is the most frequent cause of dementia, where the abnormal accumulation of beta-amyloid (Aβ) and tau lead to neurodegeneration as well as loss of cognitive, behavioral, and functional abilities.
Why it matters
This review finds that culture, preferred language, country of origin, race and ethnicity all affect scores on memory and thinking tests. It says testing procedures can favour the group the tests were developed in, and that this bias persists even after adjusting for education, income, health-care access and stress, which can lead to inaccurate diagnosis. It also notes that lower education is often mistaken for a cultural difference, and that biomarker profiles may differ between groups, so it calls for more diverse research. It is a review, not a trial, and reports no treatment.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people
- Biomarkers of Age-Related Frailty and Frailty Related to Diseases: An Exploratory, Cross-Sectional Analysis from the MAPT Study
- Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions
- Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease
- 2020 Alzheimer's disease facts and figures
- Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design
- Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose
- Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology
- Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study
- Staging of alzheimer's disease-related neurofibrillary changes